BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24015958)

  • 1. The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.
    Munk M; Memon A; Poulsen SS; Borre M; Nexo E; Sorensen BS
    Scand J Clin Lab Invest; 2013 Sep; 73(6):503-13. PubMed ID: 24015958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
    Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
    BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.
    Muraoka-Cook RS; Sandahl MA; Strunk KE; Miraglia LC; Husted C; Hunter DM; Elenius K; Chodosh LA; Earp HS
    Mol Cell Biol; 2009 Sep; 29(18):4935-48. PubMed ID: 19596786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer.
    Guo Y; Duan Z; Jia Y; Ren C; Lv J; Guo P; Zhao W; Wang B; Zhang S; Li Y; Li Z
    Oncol Lett; 2018 May; 15(5):6629-6635. PubMed ID: 29616125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo.
    Nielsen TO; Sorensen S; Dagnæs-Hansen F; Kjems J; Sorensen BS
    Br J Cancer; 2013 Jun; 108(11):2291-8. PubMed ID: 23695025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester.
    Elenius K; Corfas G; Paul S; Choi CJ; Rio C; Plowman GD; Klagsbrun M
    J Biol Chem; 1997 Oct; 272(42):26761-8. PubMed ID: 9334263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.
    Feng SM; Muraoka-Cook RS; Hunter D; Sandahl MA; Caskey LS; Miyazawa K; Atfi A; Earp HS
    Mol Cell Biol; 2009 Feb; 29(3):892-906. PubMed ID: 19047365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4.
    Rio C; Buxbaum JD; Peschon JJ; Corfas G
    J Biol Chem; 2000 Apr; 275(14):10379-87. PubMed ID: 10744726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.
    Memon AA; Sorensen BS; Melgard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2004 Dec; 91(12):2034-41. PubMed ID: 15583696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell death or survival promoted by alternative isoforms of ErbB4.
    Sundvall M; Veikkolainen V; Kurppa K; Salah Z; Tvorogov D; van Zoelen EJ; Aqeilan R; Elenius K
    Mol Biol Cell; 2010 Dec; 21(23):4275-86. PubMed ID: 20943952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
    Kiuchi T; Ortiz-Zapater E; Monypenny J; Matthews DR; Nguyen LK; Barbeau J; Coban O; Lawler K; Burford B; Rolfe DJ; de Rinaldis E; Dafou D; Simpson MA; Woodman N; Pinder S; Gillett CE; Devauges V; Poland SP; Fruhwirth G; Marra P; Boersma YL; Plückthun A; Gullick WJ; Yarden Y; Santis G; Winn M; Kholodenko BN; Martin-Fernandez ML; Parker P; Tutt A; Ameer-Beg SM; Ng T
    Sci Signal; 2014 Aug; 7(339):ra78. PubMed ID: 25140053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
    Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
    Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
    Wali VB; Gilmore-Hebert M; Mamillapalli R; Haskins JW; Kurppa KJ; Elenius K; Booth CJ; Stern DF
    Breast Cancer Res; 2014 Dec; 16(6):501. PubMed ID: 25516216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
    Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
    Fujiwara S; Hung M; Yamamoto-Ibusuk CM; Yamamoto Y; Yamamoto S; Tomiguchi M; Takeshita T; Hayashi M; Sueta A; Iwase H
    Oncotarget; 2014 Jun; 5(11):3919-30. PubMed ID: 25003574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The enhanced expression of estrogen-related receptor α in human bladder cancer tissues and the effects of estrogen-related receptor α knockdown on bladder cancer cells.
    Ye X; Guo J; Zhang H; Meng Q; Ma Y; Lin R; Yi X; Lu H; Bai X; Cheng J
    J Cell Biochem; 2019 Aug; 120(8):13841-13852. PubMed ID: 30977157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1beta1-induced migration.
    Gambarotta G; Garzotto D; Destro E; Mautino B; Giampietro C; Cutrupi S; Dati C; Cattaneo E; Fasolo A; Perroteau I
    J Biol Chem; 2004 Nov; 279(47):48808-16. PubMed ID: 15355992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Estrogen Pathway: Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens.
    Tan W; Boorjian S; Advani P; Farmer S; Lohse C; Cheville J; Kwon E; Leibovich B
    Clin Genitourin Cancer; 2015 Oct; 13(5):476-84. PubMed ID: 25981333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer.
    Ravery V; Grignon D; Angulo J; Pontes E; Montie J; Crissman J; Chopin D
    Urol Res; 1997; 25(1):9-17. PubMed ID: 9079740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking.
    Lanotte R; Garambois V; Gaborit N; Larbouret C; Musnier A; Martineau P; Pèlegrin A; Chardès T
    Cancer Sci; 2020 Jul; 111(7):2508-2525. PubMed ID: 32415868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.